You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
α2-adrenoceptor antagonist, and I2 ligand, selective over I1 sites (pKi values are 5.90, 7.22, 8.01, 7.43, and 7.7 for I1, I2, α2A, α2B, and α2C receptors respectively).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 240.69. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.15 mL||20.77 mL||41.55 mL|
|5 mM||0.83 mL||4.15 mL||8.31 mL|
|10 mM||0.42 mL||2.08 mL||4.15 mL|
|50 mM||0.08 mL||0.42 mL||0.83 mL|
References are publications that support the biological activity of the product.
Berdeu et al (1995) Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat. Eur.J.Pharmacol. 275 91 PMID: 7774667
Dabir (1986) Idazoxan: a novel pharmacological tool for the study of α2-adrenoceptors. J.Pharmacol. 17 113 PMID: 2875218
Eglen et al (1998) 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. TiPS 19 381 PMID: 9786027
Michel and Ernsberger (1992) Keeping an eye on the I site: imidazoline-preferring receptors. TIPS 13 369 PMID: 1413085
If you know of a relevant reference for Idazoxan hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Idazoxan hydrochloride, Idazoxan hydrochloride supplier, α2-adrenoceptor, alpha2-adrenoceptor, a2-adrenoceptor, a2-adrenergic, α2-Adrenergic, alpha2-Adrenergic, antagonists, I2, ligand, Receptors, Imidazoline, RX781094, RX, 781094, Adrenergic, Alpha-2, 0793, Tocris Bioscience
2 Citations for Idazoxan hydrochloride
Citations are publications that use Tocris products. Selected citations for Idazoxan hydrochloride include:
Sadeghi et al (2015) μ-Opioid receptor activation and noradrenaline transport inhibition by tapen. in rat single locus coeruleus neurons. Development 172 460 PMID: 24372103
Bucher et al (2014) Medullary NE neurons modulate local oxygen concentrations in the bed nucleus of the stria terminalis. J Cereb Blood Flow Metab 34 1128 PMID: 24714037
Do you know of a great paper that uses Idazoxan hydrochloride from Tocris? Please let us know.
Reviews for Idazoxan hydrochloride
There are currently no reviews for this product. Be the first to review Idazoxan hydrochloride and earn rewards!
Have you used Idazoxan hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.